EHC Encompass Health Corporation

Encompass Health Corp. has expanded its inpatient rehabilitation network, opening a 50-bed hospital in Lower Providence, Pennsylvania, and earlier announcing plans for a new small-format hospital in Conroe plus a 60-bed replacement facility in The Woodlands, Texas, to upgrade and extend care for patients recovering from major illnesses and injuries. The introduction of the company’s first small-format inpatient rehabilitation hospital marks a new development model that links satellite sites...

Encompass Health (EHC) has been busy expanding its inpatient rehabilitation footprint, with fresh projects in Texas and a recently opened facility in Pennsylvania giving investors more to analyze. These expansion moves arrive while Encompass Health’s share price has been gaining traction, with a 90 day share price return of 22.37% and a year to date share price return of 16.08%. This comes even though the 1 year total shareholder return declined 1.85% and the 5 year total shareholder return...

EHC is expanding near Houston with its first small-format rehab hospital and a 60-bed replacement facility in The Woodlands.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

BTSG's stronger cash flow and lower leverage could give it more flexibility to pursue acquisitions and support future growth.

Encompass Health (EHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at outpatient & specialty care stocks, starting with Encompass Health (NYSE:EHC).

Here is how Delcath Systems, Inc. (DCTH) and Encompass Health (EHC) have performed compared to their sector so far this year.

On August 5, Encompass Health (NYSE:EHC) reported second quarter results that beat its own expectations by enough to raise full year guidance twice in the same release, first on revenue and then on profit. Net operating revenue climbed 9.6% to $1.597 billion, and adjusted earnings per share rose 10.7% to $1.55. For the largest owner […]

Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

Encompass Health's capacity expansion, new facilities and North Carolina pipeline could fuel 6-8% multi-year discharge growth.

Encompass Health (EHC) has put a fresh financing framework in place, filing an omnibus shelf registration that covers potential future offerings of common and preferred stock, warrants and debt securities. See our latest analysis for Encompass Health. Encompass Health shares have eased in the past week following the shelf registration and recent $100 million senior notes issuance, although a 30 day share price return of 6.57% and a 3 year total shareholder return of 77.79% indicate momentum...

Encompass Health is back in focus as analysts edge their price targets higher, with fair value estimates moving from about US$145.25 to roughly US$148.17. Much of this shift traces to recent Q2 results, updated 2026 guidance, and a wave of research that now clusters price targets in the US$144 to US$150 range. As you read on, you will see what is driving these revisions and how to track the next moves in the Encompass Health story. Stay updated as the Fair Value for Encompass Health shifts by...

Encompass Health stock has more than doubled over the past 5 years, yet current checks still suggest the shares trade at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and to what earnings multiples imply. Encompass Health has returned about 105.2% over 5 years, which puts current investors in the position of weighing further upside against the gains already on the table. Expectations for continued cash flow generation from its rehabilitation...

EHC's rising demand, higher patient acuity and hospital expansion support growth, while rising expenses and debt remain key risks.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

This sale reduced an insider's direct equity holdings by 11%.

This sale reduced an insider's direct common stock position by 27%, though a majority of the position remains held through trusts and spousal holdings.

Tarr reduced his direct equity stake but retains roughly 268,000 shares valued at $33.7 million.

Encompass Health’s second quarter reflected robust demand for inpatient rehabilitation, with the company delivering revenue growth above Wall Street expectations and a double-digit gain in non-GAAP earnings per share. Management attributed the strong results to ongoing investments in clinical workforce development and capacity additions, as well as continued momentum in treating higher-acuity patient categories like stroke and brain injury. CEO Mark Tarr highlighted that the company’s patient ou

Revenue hit $1.597 billion with adjusted EPS up 10.7% as occupancy improved.

LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AVAH's Q2 revenues are expected to rise 9.8%, but lower PDS margins and higher costs may weigh on earnings.

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Health care services provider Encompass Health (NYSE:EHC) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.6% year on year to $1.60 billion. The company expects the full year’s revenue to be around $6.45 billion, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 4.7% above analysts’ consensus estimates.

Encompass Health (EHC) shares are in focus after the company reported second quarter revenue of about US$1.6b and earnings per share of US$1.55, both above analyst expectations, alongside higher full year 2026 revenue guidance. See our latest analysis for Encompass Health. At a share price of US$125.23, Encompass Health has a 7 day share price return of 12.75% and a 90 day share price return of 18.03%. Its 3 year total shareholder return of 80.09% points to momentum that has been building...

Encompass Health stock has delivered a 110.2% total return over the past 5 years, and at a recent price of US$125.23 the valuation checks now matter more than ever, especially since both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings based multiples currently point to the shares trading below their assessed worth. Over 5 years, Encompass Health has returned 110.2% to shareholders, which puts current buyers in the position of asking whether the latest price still...

Encompass Health (NYSE:EHC) reported second-quarter 2026 results marked by revenue, earnings and discharge growth, prompting the inpatient rehabilitation provider to raise its full-year outlook. Revenue increased 9.6% from the prior-year quarter, while adjusted EBITDA rose 9.2% to $348 million and

EHC beats Q2 earnings estimates as higher patient revenues and strong discharge growth drive results, leading the company to raise its 2026 adjusted EPS outlook.

Moby summary of Encompass Health Corporation's Q2 2026 earnings call

The headline numbers for Encompass Health (EHC) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Encompass Health (EHC) delivered earnings and revenue surprises of +4.73% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health care services provider Encompass Health (NYSE:EHC) announced better-than-expected revenue in Q2 CY2026, with sales up 9.6% year on year to $1.60 billion. The company expects the full year’s revenue to be around $6.45 billion, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was 4.7% above analysts’ consensus estimates.

EHC's higher occupancy, rising discharges and hospital expansion could support Q2 growth, but can they offset mounting operating costs?

McKesson, Encompass Health and Omega Healthcare Investors raised dividends, with payout ratios and yields showing varying levels of sustainability across the healthcare sector.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Encompass Health (NYSE:EHC) and the rest of the outpatient & specialty care stocks fared in Q1.

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Madison Small Cap Fund, managed by Madison Funds, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The small-cap market showed exceptional strength in Q2, largely due to anticipated peace in the Middle East. The Russell 2000 Index began to rally, propelled by Information Technology, Health Care, and Industrials. The […]